Novel mutations target distinct subgroups of medulloblastomaGiles Robinson, Richard J. Gilbertson, Robert Huether et al.|Nature|2012Cited by 853
Risk stratification of childhood medulloblastoma in the molecular era: the current consensusVijay Ramaswamy, Scott L. Pomeroy, Marc Remke et al.|Acta Neuropathologica|2016Cited by 650
Entrectinib in children and young adults with solid or primary CNS tumors harboring <i>NTRK</i>, <i>ROS1</i>, or <i>ALK</i> aberrations (STARTRK-NG)Ami V. Desai, Elizabeth Fox, Giles Robinson et al.|Neuro-Oncology|2022Cited by 136
Phase 1/1B trial to assess the activity of entrectinib in children and adolescents with recurrent or refractory solid tumors including central nervous system (CNS) tumors.Giles Robinson, Ami V. Desai, Amar Gajjar et al.|Journal of Clinical Oncology|2019Cited by 61
Phase II study of alisertib as a single agent for treating recurrent or progressive atypical teratoid/rhabdoid tumorSanthosh A. Upadhyaya, Amar Gajjar, Olivia Campagne et al.|Neuro-Oncology|2022Cited by 29